TY - JOUR
T1 - Phase II study of weekly docetaxel and capecitabine in patients with metastatic breast cancer
AU - Mrozek, Ewa
AU - Ramaswamy, Bhuvaneswari
AU - Young, Donn
AU - Rhoades, Chris A.
AU - Kendra, Kari
AU - Allen, Joan
AU - Moore, Tim
AU - Hauger, Marsha
AU - Watson, Holly
AU - Merriman, Nancy
AU - Nadella, Padma
AU - Villalona-Calero, Miguel
AU - Shapiro, Charles L.
N1 - Funding Information:
This trial was supported by Roche Pharmaceuticals and Aventis Pharmaceuticals.
PY - 2006/6
Y1 - 2006/6
N2 - Purpose: This phase II study evaluated the safety and efficacy of weekly docetaxel and capecitabine in patients with metastatic breast cancer. Patients and methods: Thirty-nine patients with metastatic breast cancer received 30 mg/m2 of docetaxel on days 1, 8, and 15 in combination with capecitabine 800 mg/m2 twice daily on days 1-21, repeated every 28 days. Results: The median number of treatment cycles was 4 (range, 1-20 cycles). Grade 3 toxicities per patient were asthenia (n = 7; 18%), diarrhea (n = 7; 18%), nausea/vomiting (n = 5; 13%), stomatitis (n = 5; 13%), neutropenia (n = 5; 13%), and hand-foot syndrome (n = 4; 10%). There were only 2 grade 4 toxicities, febrile neutropenia and pulmonary embolism. The overall response rate was 44% (95% confidence interval (CI), 28%-60%), median duration of response was 9.1 months (95% CI, 6.2-12 months), and median time to progression was 5.5 months (95% CI, 3.7-7.3 months). Conclusion: Weekly docetaxel with capecitabine was active with acceptable toxicities. Additional trials to define the optimal schedule of docetaxel and capecitabine are justified.
AB - Purpose: This phase II study evaluated the safety and efficacy of weekly docetaxel and capecitabine in patients with metastatic breast cancer. Patients and methods: Thirty-nine patients with metastatic breast cancer received 30 mg/m2 of docetaxel on days 1, 8, and 15 in combination with capecitabine 800 mg/m2 twice daily on days 1-21, repeated every 28 days. Results: The median number of treatment cycles was 4 (range, 1-20 cycles). Grade 3 toxicities per patient were asthenia (n = 7; 18%), diarrhea (n = 7; 18%), nausea/vomiting (n = 5; 13%), stomatitis (n = 5; 13%), neutropenia (n = 5; 13%), and hand-foot syndrome (n = 4; 10%). There were only 2 grade 4 toxicities, febrile neutropenia and pulmonary embolism. The overall response rate was 44% (95% confidence interval (CI), 28%-60%), median duration of response was 9.1 months (95% CI, 6.2-12 months), and median time to progression was 5.5 months (95% CI, 3.7-7.3 months). Conclusion: Weekly docetaxel with capecitabine was active with acceptable toxicities. Additional trials to define the optimal schedule of docetaxel and capecitabine are justified.
KW - Thymidine phosphorylase
KW - Time to progression
KW - Tripple negative
UR - http://www.scopus.com/inward/record.url?scp=33745899888&partnerID=8YFLogxK
U2 - 10.3816/CBC.2006.n.023
DO - 10.3816/CBC.2006.n.023
M3 - Article
AN - SCOPUS:33745899888
SN - 1526-8209
VL - 7
SP - 141
EP - 145
JO - Clinical Breast Cancer
JF - Clinical Breast Cancer
IS - 2
ER -